FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913190011> ?p ?o ?g. }

• W2913190011 endingPage "623" @default.
• W2913190011 startingPage "623" @default.
• W2913190011 abstract "Androgen-deprivation therapy (ADT) plus docetaxel is the standard of care in hormone-naive metastatic prostate cancer but is of uncertain benefit in a nonmetastatic, high-risk prostate cancer setting.To assess the benefit of ADT plus docetaxel in patients presenting with rising prostate-specific antigen (PSA) levels after primary local therapy and high-risk factors but no evidence of metastatic disease.This open-label, phase 3, randomized superiority trial comparing ADT plus docetaxel vs ADT alone enrolled patients from 28 centers in France between June 4, 2003, and September 25, 2007; final follow-up was conducted April 12, 2017, and analysis was performed May 2 to July 31, 2017. Patients had undergone primary local therapy for prostate cancer, were experiencing rising PSA levels, and were considered to be at high risk of metastatic disease. Stratification was by prior local therapy and PSA-level doubling time (≤6 vs >6 months), and intention-to-treat analysis was used.Patients were randomly assigned to receive ADT (1 year) plus docetaxel, 70 mg/m2 (every 3 weeks [6 cycles]), or ADT alone (1 year).The primary outcome was PSA progression-free survival (PSA-PFS). Secondary end points were PSA response, radiologic PFS, overall survival, safety, and quality of life.Overall, 254 patients were randomized (1:1) to the trial; median age, 64 years in the ADT plus docetaxel arm, 66 years in the ADT alone arm. At a median follow-up of 30.0 months, the median PSA-PFS was 20.3 (95% CI, 19.0-21.6) months in the ADT plus docetaxel arm vs 19.3 (95% CI, 18.2-20.8) months in the ADT alone arm (hazard ratio [HR], 0.85; 95% CI, 0.62-1.16; P = .31). At a median follow-up of 10.5 years, there was no significant between-arm difference in radiologic PFS (HR, 1.03; 95% CI, 0.74-1.43; P = .88). Overall survival data were not mature. The most common grade 3 or 4 hematologic toxic effects in the ADT plus docetaxel arm were neutropenia (60 of 125 patients [48.0%]), febrile neutropenia (10 [8.0%]), and thrombocytopenia (4 [3.0%]). There was no significant between-arm difference in overall quality of life.Compared with ADT alone, combined ADT plus docetaxel therapy with curative intent did not significantly improve PSA-PFS in patients with high-risk prostate cancer and rising PSA levels and no evidence of metastatic disease.French Health Products Safety Agency identifier: 030591; ClinicalTrials.gov identifier: NCT00764166." @default.
• W2913190011 created "2019-02-21" @default.
• W2913190011 creator A5002114271 @default.
• W2913190011 creator A5004900970 @default.
• W2913190011 creator A5006671522 @default.
• W2913190011 creator A5009549690 @default.
• W2913190011 creator A5010328090 @default.
• W2913190011 creator A5010708103 @default.
• W2913190011 creator A5012051564 @default.
• W2913190011 creator A5014628262 @default.
• W2913190011 creator A5016485718 @default.
• W2913190011 creator A5023813062 @default.
• W2913190011 creator A5026180389 @default.
• W2913190011 creator A5026462289 @default.
• W2913190011 creator A5032686530 @default.
• W2913190011 creator A5033220136 @default.
• W2913190011 creator A5034922000 @default.
• W2913190011 creator A5040479101 @default.
• W2913190011 creator A5040832651 @default.
• W2913190011 creator A5041906959 @default.
• W2913190011 creator A5046909112 @default.
• W2913190011 creator A5047019507 @default.
• W2913190011 creator A5049406196 @default.
• W2913190011 creator A5051181386 @default.
• W2913190011 creator A5064119598 @default.
• W2913190011 creator A5065732872 @default.
• W2913190011 creator A5067036952 @default.
• W2913190011 creator A5069166380 @default.
• W2913190011 creator A5079501252 @default.
• W2913190011 creator A5088925339 @default.
• W2913190011 date "2019-05-01" @default.
• W2913190011 modified "2023-10-14" @default.
• W2913190011 title "Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy" @default.
• W2913190011 cites W1489963450 @default.
• W2913190011 cites W1506304343 @default.
• W2913190011 cites W1810097221 @default.
• W2913190011 cites W2018998854 @default.
• W2913190011 cites W2052204509 @default.
• W2913190011 cites W2054739860 @default.
• W2913190011 cites W2063610975 @default.
• W2913190011 cites W2066131828 @default.
• W2913190011 cites W2071879495 @default.
• W2913190011 cites W2085790709 @default.
• W2913190011 cites W2110188261 @default.
• W2913190011 cites W2116839245 @default.
• W2913190011 cites W2120079339 @default.
• W2913190011 cites W2120292596 @default.
• W2913190011 cites W2130953497 @default.
• W2913190011 cites W2134896141 @default.
• W2913190011 cites W2142466432 @default.
• W2913190011 cites W2145300558 @default.
• W2913190011 cites W2150865892 @default.
• W2913190011 cites W2151114651 @default.
• W2913190011 cites W2152715017 @default.
• W2913190011 cites W2171698773 @default.
• W2913190011 cites W2196246894 @default.
• W2913190011 cites W2210989209 @default.
• W2913190011 cites W2214621962 @default.
• W2913190011 cites W2346524736 @default.
• W2913190011 cites W2414032594 @default.
• W2913190011 cites W2423925663 @default.
• W2913190011 cites W2548814073 @default.
• W2913190011 cites W2548846526 @default.
• W2913190011 cites W2598994374 @default.
• W2913190011 cites W2734617050 @default.
• W2913190011 cites W2743350540 @default.
• W2913190011 cites W2765386403 @default.
• W2913190011 cites W2777183039 @default.
• W2913190011 cites W2802540286 @default.
• W2913190011 cites W4230959758 @default.
• W2913190011 cites W4233221569 @default.
• W2913190011 cites W4238351081 @default.
• W2913190011 cites W4239330499 @default.
• W2913190011 cites W4249663626 @default.
• W2913190011 cites W4292528167 @default.
• W2913190011 cites W86544247 @default.
• W2913190011 doi "https://doi.org/10.1001/jamaoncol.2018.6607" @default.
• W2913190011 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6512307" @default.
• W2913190011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30703190" @default.
• W2913190011 hasPublicationYear "2019" @default.
• W2913190011 type Work @default.
• W2913190011 sameAs 2913190011 @default.
• W2913190011 citedByCount "22" @default.
• W2913190011 countsByYear W29131900112019 @default.
• W2913190011 countsByYear W29131900112020 @default.
• W2913190011 countsByYear W29131900112021 @default.
• W2913190011 countsByYear W29131900112022 @default.
• W2913190011 countsByYear W29131900112023 @default.
• W2913190011 crossrefType "journal-article" @default.
• W2913190011 hasAuthorship W2913190011A5002114271 @default.
• W2913190011 hasAuthorship W2913190011A5004900970 @default.
• W2913190011 hasAuthorship W2913190011A5006671522 @default.
• W2913190011 hasAuthorship W2913190011A5009549690 @default.
• W2913190011 hasAuthorship W2913190011A5010328090 @default.
• W2913190011 hasAuthorship W2913190011A5010708103 @default.
• W2913190011 hasAuthorship W2913190011A5012051564 @default.
• W2913190011 hasAuthorship W2913190011A5014628262 @default.
• W2913190011 hasAuthorship W2913190011A5016485718 @default.

• next